For Institutions
- Corporate Services
- Developers
Download
Help
About

Markets

Information

Academy

Options & Futures

IPO Subscription

Structured Products

Investment Wiki

Affiliate Program

Promotions

EN

English

简体中文

繁體中文

繁體中文（廣東話）Posts & comments will be shown in Cantonese

Search...

Quote List Quote List

Simplify Propel Opportunities ETF(SURI.US)

© 2026 Longbridge｜Disclaimer

Schedules & Filings

Schedules

Filings

Dec31

Distribution Plan(EST)

Cash dividend 0.68 USD

Dec23

Distribution Plan(EST)

Cash dividend 0.68 USD

Distribution Plan(EST)

Cash dividend 0.68 USD

View More

Event Tracking

Dec22

Viridian Therapeutics' Veligrotug Biologics License Application Accepted by FDA

12:01

Dec15

TD Cowen Raises Milestone Pharmaceuticals' Stock Rating to Buy

15:36

Dec3

Akero Therapeutics Inc. Acquisition Proposal by Novo Nordisk Approved by Shareholders

15:43

Nov13

Wells Fargo Analyst Maintains Buy Rating on Milestone Pharmaceuticals

12:17

Canaccord Genuity analyst maintains Akero Therapeutics' hold rating

12:07

Milestone Pharmaceuticals released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1235 (forecast USD -0.164)

04:00